Pipeline

Our clinical and preclinical pipeline includes wholly-owned and partnered therapeutic candidates targeting difficult-to-treat cancers and other serious diseases.

Product Candidate

Preclinical

Phase 1

Phase 2

Pivotal

Partner

Zanidatamab

Zanidatamab

HER2 x HER2 Bispecific Antibody

Zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.

Zanidatamab simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent effector function. Visit Zymeworks’ Science website to learn more about zanidatamab’s unique design.

Zanidatamab has been granted Breakthrough Therapy designation for biliary tract cancer from the FDA and the CDE in China, as well as two Fast Track designations, one for previously treated or recurrent HER2-positive biliary tract cancers (BTC) and another for first-line gastroesophageal adenocarcinoma (GEA) in combination with standard of care chemotherapy. Zanidatamab also received Orphan Drug designation for the treatment of biliary tract and gastric cancers in the United States and for gastric cancer in the European Union.

Zymeworks has entered into separate agreements with each of BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab throughout various countries around world.

Product Status

Pivotal

Indications

  • Biliary Tract Cancers
  • Breast Cancer
  • Gastroesophageal Adenocarcinomas
  • Colorectal Cancer
  • HER2-Expressing Cancers

Partner

Technology

Product Candidate

1st-Line Gastroesophageal Adenocarcinomas

HERIZON-GEA-01
Chemotherapy Combination

Phase: Pivotal

Partner:

Product Candidate

1st-Line Gastroesophageal Adenocarcinomas

HERIZON-GEA-01
Chemotherapy Combination

Phase: Pivotal

Partner:

Product Candidate

2nd-Line Biliary Tract Cancers

HERIZON-BTC-01
Monotherapy
FDA Breakthrough Therapy Designation

Phase: Pivotal

Partner:

Product Candidate

1st-Line Gastrointestinal Cancers

Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Chemotherapy Combination

Phase: Pivotal

Partner:

Product Candidate

Late-Line Breast Cancer

Combination with Palbociclib & Fulvestrant

Phase: Phase 2

Partner:

Product Candidate

HER2-Expressing Cancers

Monotherapy & Chemotherapy Combination

Phase: Pre-clinical

Partner:

Zanidatamab Zovodotin

Zanidatamab Zovodotin

HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC)

Zanidatamab zovodotin (ZW49) is a HER2-targeted bispecific antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin platforms technologies. Zanidatamab zovodotin combines the unique design of zanidatamab with the addition of a proprietary cytotoxin. Zanidatamab zovodotin delivers a novel auristatin (cell-killing compound) to tumor cells via a cleavable linker by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.

Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents.

Product Status

Phase 1

Indications

  • HER2-Expressing Cancers

Partner

Technology

Preclinical

Product Candidate

ZW191

Folate Receptor-⍺ Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate

Phase: Preclinical

ZW191

Folate Receptor-⍺ Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate

ZW191 is an antibody-drug conjugate that is engineered to target a protein called folate receptor-⍺ (FR⍺) that is found on a variety of tumours. ZW191 delivers a toxic chemotherapy, topoisomerase-1 inhibitor, to these tumour cells to kill the cancer.

ZW191 is currently in the IND-enabling stage of development.

Product Status

Preclinical

Indications

  • Ovarian Cancer & Gynaecological Cancers

Technology

Product Candidate

ZW171

2+1 MSLN x CD3 Bispecific Antibody

Phase: Preclinical

ZW171

2+1 MSLN x CD3 Bispecific Antibody

ZW171 is a bispecific antibody that is designed to co-engage tumor cells and immune cells (T cells) to enable T cell-mediated killing of tumor cells. ZW171 binds the tumor target mesothelin (MSLN) which is expressed on many different tumors including pancreatic and ovarian cancer. Our team engineered and optimized the antibody design using the Azymetric™ and EFECT™ technologies.

ZW171 is currently in preclinical development, projected to enter Phase I clinical trials in 2024.

Product Status

Preclinical

Indications

  • Solid Tumors

Technology

Product Candidate

ZW251

Glypican-3 Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate

Phase: Preclinical

ZW251

Glypican-3 Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate

ZW251 is the first antibody-drug conjugate engineered to target a protein called glypican-3 (GPC3), which is found on a difficult to treat liver cancer, hepatocellular carcinoma (HCC). The antibody is uniquely designed to bind strongly to the GPC3 protein, then deliver its toxic chemotherapy, topoisomerase-1 inhibitor, to kill the cancer cells.

ZW251 is currently in the IND-enabling stage of development.

Product Status

Preclinical

Indications

Undisclosed

Technology

Product Candidate

ZW220

NaPi2b Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate

Phase: Preclinical

ZW220

NaPi2b Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate

ZW220 is an antibody drug conjugate engineered to target a protein called sodium-dependent phosphate transporter 2b (NaPi2b). The antibody is designed to bind to the NaPi2b protein that is found on some ovarian and lung tumours, and deliver its toxic chemotherapy, a topoisomerase1 inhibitor, to kill the cancer.

ZW220 is currently in the IND-enabling stage of development.

Product Status

Preclinical

Indications

Undisclosed

Technology

Partners

Product Candidate

Bispecific

Phase: Pre-clinical

Partner:

Bispecific

Product Status

Pre-clinical

Indications

  • Oncology

Partner

Technology

Product Candidate

JNJ-78278343

(CD3 x KLK2)

Phase: Phase 1

Partner:

JNJ-78278343

(CD3 x KLK2)

Product Status

Phase 1

Indications

  • Castration-Resistant Prostate Cancer

Partner

Technology

Product Candidate

Bispecific

Phase: Pre-clinical

Partner:

Bispecific

Product Status

Pre-clinical

Indications

  • Undisclosed

Partner

Technology

Product Candidate

Bispecific

Phase: Pre-clinical

Partner:

Bispecific

Product Status

Pre-clinical

Indications

  • Immuno-Oncology

Partner

Technology

Product Candidate

Bispecific

Phase: Pre-clinical

Partner:

Bispecific

Product Status

Pre-clinical

Indications

  • Infectious Disease

Partner

Technology

Product Candidate

Undisclosed

Phase: Pre-clinical

Partner:

Undisclosed

Product Status

Pre-clinical

Indications

  • Undisclosed

Partner

Technology

Product Candidate

Bispecific

Phase: Pre-clinical

Partner:

Bispecific

Product Status

Pre-clinical

Indications

  • Dermatology

Partner

Technology